76 results
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
9:00am
and benefits of treatment with SIMLANDI prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3 … immunosuppressants.
Consider the risks and benefits of TNF blocker-treatment, including SIMLANDI, prior to initiating therapy in patients with known malignancy
6-K
EX-99.1
ALVO
Alvotech
16 Apr 24
Current report (foreign)
6:30pm
. Consider the risks and benefits of treatment prior to initiating use of SELARSDI in patients with a chronic infection or a history of recurrent
6-K
EX-99.1
ALVO
Alvotech
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
, predominantly Icelandic krona and euros.
Income tax benefits: The income tax benefit increased by $61.3 million for the year ended December 31, 2023
6-K
EX-99.1
mi9zw5q
23 Feb 24
Current report (foreign)
8:39pm
F-3
EX-4.5
hkx65pe7r58j8sni4o2
20 Oct 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.2
y3cvqnlzmjk
31 Aug 23
Current report (foreign)
8:00am
424B3
rmytfpsfzwcfm jld
24 Jul 23
Prospectus supplement
8:03am
424B3
w9si sitwaa0hgd
24 Jul 23
Prospectus supplement
8:00am
F-3
vrrih
14 Jul 23
Shelf registration (foreign)
4:56pm
POS AM
kg6 q1z72z9wsmap4
14 Jul 23
Prospectus update (post-effective amendment)
4:45pm
424B3
do1ku245 jfjh6251y1
17 Nov 22
Prospectus supplement
5:21pm
424B3
w6u 36ewkqb
17 Nov 22
Prospectus supplement
5:21pm
6-K
EX-99.9
f8plsl
17 Nov 22
Alvotech Secures Financing Facilities of Approximately $136 Million
5:18pm
6-K
EX-99.5
0g4n q8t00m
17 Nov 22
Alvotech Secures Financing Facilities of Approximately $136 Million
5:18pm
6-K
EX-99.4
01gsltr563t
17 Nov 22
Alvotech Secures Financing Facilities of Approximately $136 Million
5:18pm
424B3
k1eesxgm
21 Sep 22
Prospectus supplement
4:59pm
424B3
okw 6z8jx
21 Sep 22
Prospectus supplement
4:54pm
F-1/A
ob63xtz8n o2
14 Sep 22
Registration statement (foreign) (amended)
4:58pm